Page 1

ikena ONCOLOGY Ikena Oncology Reports Third Quarter 2021 Financial Results and Corporate Update November 10 , 2021 IND for IK - 930 accepted by FDA ; Phase 1 clinical trial expected to initiate in early 2022 Progressing RAS pathway research programs with multiple development candidates expected in the next 18 months Investigator - initiated trial launched evaluating IK - 007 in combination with eribulin in recurrent / metastatic inflammatory breast cancer BOSTON , Nov. 10 , 2021 ( GLOBE NEWSWIRE ) -- Ikena Oncology , Inc. ( Nasdaq : IKNA , “ Ikena ” , “ Company ” ) , a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways , today announced financial results for the quarter ended September 30 , 2021 . The Company also provided an update across the organization and pipeline , including the acceptance of an IND for their TEAD inhibitor , IK - 930 , as they advance it towards initiation of a Phase 1 clinical trial for patients with tumors known to have high incidence of Hippo pathway genetic alterations . In addition to the Company's progress on IK - 930 , Ikena is driving several programs targeting the RAS pathway . Emerging data from discovery and translational efforts have focused the team on key nodes in the RAS pathway that provide potential for clinical advancement of targeted therapies both as single agents and in combination to overcome therapeutic resistance in RAS mutated cancers . This work includes further efforts on ERK5 biology and chemistry optimization prior to candidate nomination , but also highlights new opportunities in the pathway . Multiple development candidates are expected to emerge from these RAS discovery programs over the next 18 months . " Patients with mutations in the Hippo and RAS pathways represent cancer populations with significant unmet needs . At Ikena , we are committed to generating deep scientific support for our approach in these pathways and in the identification of therapies that could best treat their individual disease , " commented Mark Manfredi , Ph.D. , Chief Executive Officer of Ikena . " The team has done tremendous work exploring TEAD biology , advancing IK - 930 , and generating robust translational data to optimize the clinical development plan . The IND acceptance is a foundational milestone for our targeted oncology portfolio and for our approach to biomarker - driven cancer treatments . The progress across the entirety of our pipeline demonstrates our commitment to science and medicine that will lead to better therapies with the best chance of helping patients . " Summary of Recent Pipeline Progress and Corporate Update • IK - 930 : TEAD Inhibitor in the Hippo Signaling Pathway • IND accepted by the Food and Drug Administration ( FDA ) ; clinical trial expected to initiate in the first quarter of 2022 • Program data was shared at the AACR - NCI - EORTC 2021 Virtual International Conference on Molecular Targets and Cancer Therapeutics ■ Data highlighted translational methods using a novel assay developed by Ikena and suggested YAP / TAZ activity could be a potential biomarker in determining patients that could benefit from TEAD inhibition ■ Preclinical data showed the importance of the Hippo pathway in resistance to EGFR and MEK inhibition and the potential of therapeutic combinations for patients , supporting our plans to evaluate combinations of IK - 930 in multiple tumor types • RAS Pathway : Progressing Multiple Targets and Novel Approaches o Ikena has been expanding its discovery and translational research efforts in the RAS pathway beyond ERK5 , with a particular focus on targeting nodes in the pathway that have potential for monotherapy and combinations both intra- pipeline and with other targeted agents • Continued drug discovery and additional translational efforts are being conducted prior to potential ERK5 candidate nomination . The RAS pathway discovery programs are expected to result in multiple targeted oncology development candidates in the next 18 months • IK - 175 & IK - 412 : AHR Inhibitor and Kynurenine Degrading Enzyme Programs in Collaboration with Bristol Myers Squibb • IK - 175 is currently being evaluated in a Phase 1 study to assess its impact in solid tumors and in urothelial carcinoma though aryl hydrocarbon receptor ( AHR ) inhibition ■ The study expanded its monotherapy cohort in urothelial carcinoma earlier this year and recently completed